
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc demonstrates a strong growth trajectory, with expectations of a $10-15 million sequential EBITDA improvement in the third and fourth quarters, culminating in projected figures of $32.5 million for Q3 and $45 million for Q4. The company is capitalizing on its robust cross-selling abilities, upselling risk-based products to large clients, and securing new evergreen contracts, positioning it well for outsized growth in the coming years. Furthermore, with a Medical Expense Ratio (MER) anticipated to improve significantly and top-line growth surpassing the mid-teens revenue growth target, Evolent Health is positioned for substantial profitability and market leadership in specialty-focused value-based care.
Bears say
Evolent Health Inc. is projected to experience a significant decline in revenue, specifically losing approximately $100 million from its legacy Performance Suite, which is contributing to an estimated total revenue of about $850 million for that segment. The company has also lowered its earnings per share (EPS) estimates for fiscal years 2026 and 2027, indicating a reduction in expected profitability from previous forecasts. In addition, while general and administrative costs are expected to decline due to efficiency initiatives, the overall financial outlook remains bleak due to stagnant EBITDA performance, with Q1 targeted at just $20 million and anticipated flat growth in Q2.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares